Sickle Cell: Stroke
Clinical Pathways promote evidence-based, safe, and high-value care for patients by providing clinical recommendations and standard processes. They are developed by multidisciplinary committees of subject matter experts, informed by a methodical review of available evidence and consensus among committee members.
Clinical Pathways:
- Stroke: Sickle Cell Patient in ED/Inpatient Algorithm
- Stroke: Sickle Cell Patient in PICU/Inpatient Algorithm
Inclusion and exclusion criteria
Inclusion:
- Patient with sickle cell disease presents with signs/symptoms of suspected stroke.
Committee members involved in the development:
- N. Tabassum Iqbal MD | Hematology/Oncology/BMT | Committee chair
- M. Files MD | Neurology | Committee member
- R. Khalid MD | Neurology | Committee member
- M. Sharma MD, MPH | Hematology/Oncology/BMT | Committee member
- J. Rilinger MD | Critical Care Medicine | Committee member
- J. Flint MD | Critical Care Medicine | Committee member
- C. Tarantino MD | Emergency Medicine | Committee member
- V. McDougall Kestner MD | Emergency Medicine | Committee member
- J. Bartlett PhD, RN | Evidence Based Practice | Committee member
Publication dates:
- Finalized date: Aug. 30, 2018; June 2021
- Next expected revision date: June 2024
If you have any questions regarding this content, or identify a broken link, please email evidencebasedpractice@cmh.edu.
These pathways do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at the time. It is impossible to anticipate all possible situations that may exist and to prepare a pathway for each. Accordingly, these pathways should guide care with the understanding that departures from them may be required at times.